The FDA granted an appeal to an earlier decision, resetting tenapanor on a path toward approval for treating hyperphosphatemia in patients undergoing dialysis.
A single-center study shows lower mortality and fewer cardiovascular events in patients seen in a follow-up clinic after discharge for acute kidney injury, stressing the "importance of post-AKI care."